Semaglutide Injections Recalled Over Sterility Concerns

This alert was compiled from official government recall data published by the FDA using automated analysis. All facts are sourced directly from official records. Last verified April 30, 2026.

Imagine injecting a medication you believe is helping you, only to discover it might be contaminated. That's the unsettling reality facing some people who received a specific batch of Semaglutide-Glycine-Cyanocobalamin Injectable from PAYLESS COMPOUNDERS, LLC. The company has initiated a product recall in the United States due to concerns about sterility. Your health could be at risk.

• Product: Semaglutide-Glycine-Cyanocobalamin Injectable
• Strength: 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials
• Company: PAYLESS COMPOUNDERS, LLC
• Reason: Lack of Sterility Assurance
• Affected Units: 91 vials
• Lot Number: 01-27-2026@14S.5
• Recall Date: April 22, 2026

The Danger: A Serious Lack of Sterility

This isn't a minor issue. A lack of sterility in injectable medications can lead to severe infections. These infections are potentially life-threatening. The consequences can be devastating.

If the injectable product is not sterile, using it puts you directly at risk of bacterial or fungal infections. These infections can be difficult to treat. They may require hospitalization and intensive care. It's a gamble nobody wants to take with their well-being.

This particular product, Semaglutide-Glycine-Cyanocobalamin Injectable, is an Rx-only medication being recalled by PAYLESS COMPOUNDERS. It's vital to know if you received medication dispensed by them.

Who Is Affected By This Product Recall in the United States?

The recall is currently limited to Oregon. However, U.S. consumers should remain vigilant. If you obtained this medication from Northwest Compounders (Beaverton, OR), or PAYLESS COMPOUNDERS, LLC, pay close attention to the lot number. This impacts American shoppers who have used this potentially tainted injectable.

The affected lot number is 01-27-2026@14S.5. Only 91 vials are subject to this product recall. The severity is classified as Class II, meaning use of the product could cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Unlike medications you might pick up at major retailers like Walmart, Target, or Costco, this injectable was dispensed through a compounding pharmacy. That means it was specifically prepared for an individual. This makes tracking down affected individuals more challenging but also more critical.

What You Should Do Right Now

Take immediate action to protect your health. Don't delay.

1. Immediately stop using Semaglutide-Glycine-Cyanocobalamin Injectable with lot number 01-27-2026@14S.5 from PAYLESS COMPOUNDERS, LLC.
2. Contact your healthcare provider immediately to discuss the potential risks and determine if you need medical evaluation or treatment.
3. If you experienced any adverse reactions or think you've developed an infection, seek immediate medical attention and tell your doctor that you may have received a non-sterile injection.
4. Contact PAYLESS COMPOUNDERS, LLC, to inquire about the recall process and how to properly dispose of the affected medication.
5. Report any adverse events related to this medication to the FDA's MedWatch program.

Why This Recall Matters to American Shoppers

This recall isn't just about one product; it underscores the importance of quality control in compounding pharmacies. It highlights a gap in assurance for the sterility of medications some patients are prescribed. It serves as a cautionary tale for all U.S. consumers.

PAYLESS COMPOUNDERS, LLC, is taking steps to manage the situation. However, previous incidents at compounding pharmacies have shown that even with best efforts, contamination can occur. This is why careful oversight is a must.

Given that the FDA has issued numerous recalls this year, it's crucial to stay informed about potential health risks associated with medications from these sources. Pay attention. Protect yourself.

How to Identify the Recalled Product

Identifying the recalled product is essential. First, check the name: Semaglutide-Glycine-Cyanocobalamin Injectable. Second, verify the dosage: 2.5 mg, 5 mg, or 1 MG/ML in 0.5 mL vials. These are prescription-only medications.

Third, and most importantly, locate the lot number on the vial's label. The recalled lot is 01-27-2026@14S.5. If your vial matches this information, it is part of the recall. Do not use it.

The date of the recall announcement is April 22, 2026. You can use this date to cross-reference with any information you received when you obtained the medication. This will help you confirm whether your medication is potentially affected. Double-check everything.

This recall was announced by the U.S. Food and Drug Administration (FDA). For the official notice and complete details, visit www.fda.gov.

Frequently Asked Questions

Q: What is Semaglutide-Glycine-Cyanocobalamin Injectable used for?

This is a compounded formulation potentially used for weight management or other related therapies. It requires a prescription from a healthcare provider.

Q: What does "lack of assurance of sterility" mean?

It means there's no guarantee the injectable was free from harmful bacteria or other microorganisms during production. This could lead to infection if injected.

Q: What should I tell my doctor if I used the recalled medication?

Inform your doctor that you used Semaglutide-Glycine-Cyanocobalamin Injectable from lot number 01-27-2026@14S.5. Tell them about any symptoms you are experiencing.

Q: How do I report an adverse event related to this recalled product?

You can report any adverse events to the FDA's MedWatch program online or by phone. Your doctor can assist you with this as well.

Q: Will I receive a refund for the recalled medication?

Contact PAYLESS COMPOUNDERS, LLC, directly to inquire about their refund or replacement policy for the recalled product. They can provide specific details.